Bayer names Philip Blake to lead U.S. operations
PITTSBURGH — Bayer on Tuesday announced that on July 1, Philip Blake will become senior Bayer representative USA, following a common company practice of assigning this oversight role to a senior executive already holding a significant business role or roles within the region.
“Phil Blake is a highly valued and respected leader at Bayer,” stated Richard Pott, member of the management board of Bayer. “Having been with Bayer for more than 30 years, he brings a wealth of experience to this new role.”
In this new role, Blake assumes leadership of Bayer corporate operations in the U.S. from Greg Babe, who recently announced his planned retirement from Bayer. In 2011, Bayer’s U.S. operations recorded annual sales of $9.8 billion.
Blake has also been named Bayer healthCare representative USA and will maintain his position as U.S. region head of Bayer HealthCare Pharmaceuticals, the U.S.-based specialty pharmaceuticals division of Bayer HealthCare.
With construction underway for a new consolidated U.S. Bayer HealthCare site in Whippany, N.J., Blake will maintain his primary office in that location.
Blake was previously head of Bayer Inc., a Canadian subsidiary of Bayer AG, and head of Bayer HealthCare in Canada. In his 30-year career with Bayer, Blake has held leadership positions around the world focusing on global strategic product marketing, business development, clinical planning, product development and sales management.
Blake attended Bristol University and Oxford University Business School in the United Kingdom, with extended business training at INSEAD Fontainbleu in Paris, France, and the Wharton Business School in Philadelphia. He is also a Chartered Corporate Director – earning this designation in 2006 from the Directors College at the DeGroote School of Business, McMaster University.
He is married and has two children.
Healthcare providers driving surge in downloads of healthcare-related apps
NEW YORK — The market for healthcare-related software apps for use in mobile devices has grown and will continue to grow quickly, according to Kalorama Information report released Tuesday. The market for mobile medical apps was worth about $150 million in 2011.
The conversion of major healthcare organizations to electronic medical record systems and the breadth of medical apps available are driving purchases, the medical research firm noted. Not only is the medical community using smartphones and their applications for basic work, but it’s reporting the use of smartphones to perform some of the work that would have previously been done on a desktop or laptop computer.
The growing use of mobile devices and medical applications for these devices has prompted the Food and Drug Administration to provide more oversight in this segment, Kalorama noted.
"The medical app market is growing at a faster rate than the standard app market," stated Melissa Elder, author of the report. "They are being heavily utilized by professionals and welcomed by healthcare organizations seeking to make workers more productive."
While the overall mobile app market is expected to continue to display strong double-digit growth through 2016, the medical app market will also continue to grow but at a faster rate. Although they make up just 1% to 2% of the entire market for mobile apps, Kalorama finds that healthcare apps will grow 25% annually over the next five years, compared to 23% growth estimated for the standard apps market. The growing number of healthcare professionals utilizing these apps in everyday business activities is contributing to the market segment growing at a faster rate than some other categories of apps.
Part of the revenue growth is being driven by prices rather than volume, according to the report. Despite the higher price tag for most medical apps (averaging $15 per app), the number of downloads is lower than other categories, keeping medical apps high growth-wise but on the lower end of total dollars earned in comparison to other app areas.
Fans for the Cure partners with Walgreens on prostate cancer awareness baseball tour
NEW YORK — Ed Randall’s Fans for the Cure on Wednesday announced that it once again has teamed with Walgreens to increase awareness about prostate cancer in baseball ballparks across the United States. For the second year, Fans for the Cure and Walgreens are sponsoring a Baseball Road Trip, designed to strike out prostate cancer by encouraging men to "visit your doctor to check for prostate cancer, get your PSA score and stay in the game."
The road trips kicks off on Father’s Day, June 17.
"We’re humbled by the ongoing support that our charity is receiving from Minor League Baseball, as well as Walgreens," stated Ed Randall, CEO Ed Randall’s Fans for the Cure. "The work being done in dozens of ballparks this summer to educate men about prostate cancer awareness will promote better health, as well as save lives. Many men are unaware that a simple blood test can help a doctor detect prostate cancer in its early stages, when it can usually be cured."
To view a complete listing of ballparks hosting prostate cancer awareness events, go to http://fans4thecure.org/calendar.